Advanced therapy manufacturing is still in its infancy says JIB’s Parviz Shamlou, who looks to digital processes and advanced AI to improve production going forward. Legacy biopharmaceuticals such as proteins and monoclonal antibodies are well-proven and relatively easy to scale-up. A single batch from a 20,000 L bioreactor, for example, will provide sufficient drug product to treat thousands of patients. However, cell and gene therapies represent a very different model, says Parviz Shamlou, executive director at the Jefferson Institute for…